A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants

开始日期2008-12-01

申办/合作机构

Novartis AG

100 项与 Pertussis acellular and DTaP vaccine candidates (Novartis Vaccines) 相关的临床结果

登录后查看更多信息

100 项与 Pertussis acellular and DTaP vaccine candidates (Novartis Vaccines) 相关的转化医学

登录后查看更多信息

100 项与 Pertussis acellular and DTaP vaccine candidates (Novartis Vaccines) 相关的专利（医药）

登录后查看更多信息

330

项与 Pertussis acellular and DTaP vaccine candidates (Novartis Vaccines) 相关的文献（医药）

2024-08-01·Journal of Racial and Ethnic Health Disparities

Timely Prenatal and Infant Pertussis Vaccine Uptake in an Integrated Health System

Article

作者: Tseng, Hung Fu ; Ackerson, Bradley ; Becerra-Culqui, Tracy

BACKGROUNDHispanic infants bear the burden of pertussis infection. We examined pertussis protection from vaccination in infants with US-born and foreign-born Hispanic mothers.METHODSRetrospective cohort study of infants up to 1 year of age. Secondary data of mothers with continuous membership since the 27th week of pregnancy with infants born 1/1/2012-12/31/2017 in an integrated health care delivery organization, which broadly represent the Southern California population.RESULTSForeign-born Hispanic mothers had higher prenatal tetanus, diphtheria, acellular pertussis (Tdap) uptake compared to US-born white mothers [adjusted risk ratio (aRR): 1.04, 95% confidence interval (CI): 1.03, 1.05]. Infants with mothers on Medicaid insurance disproportionately did not enroll in the health plan by the time they were eligible for their first dose of the DTaP vaccine (68.4%). Once initiating the infant vaccine series, foreign-born Hispanic mothers more likely adhered than US-born white mothers (aRR: 1.05, CI: 1.02, 1.08).DISCUSSIONIn an integrated health system, disparities in vaccine uptake can be minimized. Infants who are born to mothers with Medicaid insurance and are not enrolled in the health plan after birth may be under-protected from pertussis.

2024-05-01·American Journal of Perinatology

Routine Maternal Vaccine Uptake during the COVID-19 Pandemic

Article

作者: Miao, Di ; Ratan, Bani M. ; Cotter, Savannah ; Taylor, Lauren ; Grace, Rebecca

Objective This study examines the impact of the coronavirus disease 2019 (COVID-19) pandemic on influenza and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine uptake in a pregnant, low-income population. Study Design This retrospective cohort study included women initiating prenatal care before (May–November 2019) or during the COVID-19 pandemic (May–November 2020) at two large Medicaid clinics. All patients entered prenatal care before 20 weeks and delivered full-term. Medical records were reviewed for vaccine uptake and demographic data. Multivariate logistic regression analysis was used to compare vaccination rates prior to and during the COVID-19 pandemic. Additional analysis was performed to identify association of demographic factors with vaccine uptake. IRB approval was obtained for this study. Results A total of 939 patients met inclusion criteria, with 462 initiating care prior to and 477 initiating care during the COVID-19 pandemic. Influenza vaccination uptake was 78% (362/462) in the prepandemic group, significantly decreasing to 61% (291/477) in the pandemic group (p <0.01, odds ratio [OR] = 0.38, confidence interval [CI]: 0.26–0.53). Tdap vaccination uptake was 85% (392/462) in the prepandemic group, significantly decreasing to 76% (361/477) in the pandemic group (p <0.01, OR = 0.56, CI: 0.40–0.79). The decrease in influenza vaccine uptake was most significant in non-Hispanic Black patients, decreasing from 64% (73/114) in the prepandemic group to 35% (35/101) in the pandemic group (p <0.01, OR = 0.30, CI: 0.17–0.52), while there was no significant difference in age or parity in relation to vaccination status. Conclusion Routine vaccination uptake significantly decreased during the COVID-19 pandemic in a low-income population of pregnant women, with decrease more pronounced on influenza vaccine than on Tdap vaccine uptake, especially in non-Hispanic Black patients. Key Points

2024-03-24·Cureus

Financial Burden as a Potential Barrier to Vaccine Completion in Post-hematopoietic Stem Cell Transplant Patients in Japan

Article

作者: Kasahara, Kei ; Fujikura, Hiroyuki ; Ogawa, Taku ; Hirai, Nobuyasu ; Imakita, Natsuko

Introduction The administration of routine vaccinations to patients following hematopoietic stem cell transplantation (HSCT) is highly recommended. However, studies examining reasons for not completing vaccination in post-HSCT patients are lacking. Method We reviewed the medical records of patients who sought vaccination following HSCT from January 2012 to December 2018 at the Center for Infectious Diseases, Nara Medical University. Results Information regarding patients' backgrounds, administered vaccines, and reasons for not administering recommended vaccines was collected for the study. Thirty-five patients (22 men and 13 women) with a median time from HSCT to the first visit of 25 months were enrolled. Vaccine coverage was highest for diphtheria, tetanus, and acellular pertussis (DTaP) at 89% (31 patients), followed by 23-valent pneumococcal, measles/rubella/mumps, and Japanese encephalitis at 71% (25 patients), 71% (25 patients), and 63% (22 persons), respectively. However, vaccine coverage for hepatitis B, 13-valent pneumococcal, and Hib was low at 26% (three patients), 11% (four patients), and 40% (14 patients), respectively. The reason for not completing the recommended vaccination series was not provided for most cases; however, the economic barrier was cited for all vaccines. Discussion This study identified several cases in Japan where individuals stopped completing post-HSCT vaccinations due to financial constraints. Larger-scale studies may be necessary in Japan in the future for further investigation.

100 项与 Pertussis acellular and DTaP vaccine candidates (Novartis Vaccines) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白喉	临床1期	比利时	Novartis Vaccines & Diagnostics, Inc.	-
破伤风	临床1期	比利时	Novartis Vaccines & Diagnostics, Inc.	-
百日咳	临床1期	比利时	Novartis Vaccines & Diagnostics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00806195 (CTgov)	临床3期	脑膜炎 \| 脑膜炎球菌感染	7,744	Hepatitis A Virus+Varicella Vaccine+DTaP (Diptheria, Tetanus, Pertussis) Vaccine+MenACWY-CRM197 (MenACWY-CRM197 + Routine Vaccines (Detailed))	鹹鏇窪壓觸遞廠獵醖構(製艱製範網獵鏇餘遞憲) = 膚築衊積淵鏇衊餘憲餘蓋觸鹹鏇廠壓選襯蓋簾 (憲鑰糧觸選餘淵獵範繭, 積繭膚糧鹽築簾鹽範積 ~ 積淵獵製衊糧醖獵膚築) 更多	-	2013-07-09
				Hepatitis A Virus+Varicella Vaccine+DTaP (Diptheria, Tetanus, Pertussis) Vaccine (Routine Vaccines (Detailed))	鹹鏇窪壓觸遞廠獵醖構(製艱製範網獵鏇餘遞憲) = 淵範糧鑰願鑰淵鹹憲願蓋觸鹹鏇廠壓選襯蓋簾 (憲鑰糧觸選餘淵獵範繭, 鬱鹽網觸獵遞製鏇憲淵 ~ 範積糧齋願築鬱膚願蓋) 更多